People
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
Legal battles are continuing between the Rockwell Medical Board of Directors and two senior executives who were fired earlier this year.
More and more pharma companies follow the trend of planning initial public offerings on the Hong Kong Stock Exchange. Another trend following this path is the number of prominent investment bankers who have left their firms for biotech companies in the former British colony.
It was a slow week as far as changes were made at the executive level in the biopharma industry. Still, three companies made key appointments that will potentially spur strategic growth for stakeholders.
Martin Shkreli has been blogging about the biopharma industry from prison.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Shares of MiMedx are down more than 31 percent this morning following the abrupt resignation of Board Chairman and Chief Executive Officer Parker H. “Pete” Petit. Additionally, William C. “Bill” Taylor resigned as president and chief operating officer.
Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.
With the end of June, numerous biotechs shored up their boards of directors and other advisory boards with new members as the companies continued to shape their future strategies.
A recent change to the definition of “smaller reporting company” by the U.S. Securities and Exchange Commission earned praise from the Biotechnology Innovation Organization.
PRESS RELEASES